Recursion Pharmaceuticals Inc Clas (RXRX)

EBITDA

-$444.45M

TTM · Period ending: · USD

RXRX logo

RXRX EBITDA

Latest reported-$444.45M
RXRX EBITDA (-$59.39M → -$444.45M)
High-resolution chart · PNG

RXRX ebitda history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Recursion Pharmaceuticals Inc Clas EBITDA — Annual fiscal periods (USD)
Period endingEBITDA (USD)
-559,384,000
-426,722,000
-307,629,000
-227,665,000
-175,122,000
-81,703,000
-59,390,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.